What is DXCM's market cap?

$33B, based on the Nov 4 close of $88.48.

What is DXCM's P/E ratio?

33.3× trailing-twelve-month earnings of $991M.

Does DexCom pay a dividend?

No regular cash dividend has been paid in the last year.

How much of DXCM is sold short?

15.7M shares, 4.2% of float, as of Oct 15, 2026.

What sector is DXCM in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · DXCMHealthcareSurgical Instruments

DexCom, Inc. (DXCM)

$88.48+6.64%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$87.94▲ 45.52% in range

Nov 3, 2025Low $54.84 · High $92.34Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

DexCom closed at $88.48 on Nov 4, up 6.64%, 4.2% below its 52-week closing high. Volume of 5.3M shares was 1.08× its 20-day average (close to normal).

Split-adjusted performance: +6.1% over one month, +46.6% over six months, +46.4% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.34B, up 11.2% from a year earlier, with a net margin of 20.5%.

Short interest was 15.7M shares at the Oct 15 settlement, up 11.9% from the prior report (4.2% of float, 4.8 days to cover).

Market cap$33.00B373.0M shares

Revenue · quarter$1.34B+11.2% YoY

Diluted EPS$0.72+2.9% YoY

P/E · TTM33.3×P/S 6.5×

Net margin20.5%Gross 64.3%

Dividend yieldNone

52-week range54.84 – 92.34−4.2% from high

Volume5.3M1.08× 20-day avg

Volatility · 60d31.9%Annualised

Short % of float4.2%4.8 days to cover

Net cash$574.2MCash $1.82B

Next earnings—Not scheduled

Split-adjusted performance

1W +12.5%1M +6.1%3M +6.6%6M +46.6%YTD +33.3%1Y +46.4%3Y +4.2%5Y −36.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum82

Revenue growth54

Net margin92

Value (low P/E)40

Size95

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short15.7M+11.9% vs prior

Days to cover4.8Settled Oct 15

% of float4.2%

Short vol. 10d41.6%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
DXCMDexCom	$88.48	+6.64%	+46.6%	+11.2%	20.5%	33.3	$33.00B
RMDResMed	$240.51	+5.91%	+14.7%	+5.9%	29.6%	21.2	$33.83B	Compare
MDLNMedline	$40.35	+18.36%	−4.0%	—	0.8%	—	$35.40B	Compare
WSTWest Pharmaceutical Services	$408.78	+0.44%	+30.8%	+8.7%	24.5%	44.6	$28.48B	Compare
BDXBecton, Dickinson and	$209.19	+5.56%	+44.5%	+5.4%	7.6%	60.6	$56.98B	Compare
BSXBoston Scientific	$45.82	+5.33%	−18.2%	+1.4%	11.3%	19.0	$66.40B	Compare
SOLVSolventum	$89.35	+5.42%	+25.9%	+2.2%	4.2%	10.6	$15.21B	Compare
GKOSGlaukos	$246.70	+5.86%	+82.4%	+58.0%	1.0%	—	$14.60B	Compare
BAXBaxter International	$26.50	+3.96%	+56.1%	+5.0%	9.9%	—	$13.71B	Compare

News about DexCom

All news →

DexCom to Launch 15-Day G7 CGM System in Canada This NovemberZacks Investment Research · 1d ago▲ Positive DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins RiseZacks Investment Research · 5d ago▲ Positive DexCom Gears Up to Report Q3 Results: How to Play the Stock?Zacks Investment Research · Oct 26, 2026Neutral DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT StudyZacks Investment Research · Oct 20, 2026▲ Positive Here's Why You Should Retain DexCom Stock in Your Portfolio for NowZacks Investment Research · Oct 13, 2026Neutral

Quick answers

What does DexCom do?: DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
What is DXCM's market cap?: $33B, based on the Nov 4 close of $88.48.
What is DXCM's P/E ratio?: 33.3× trailing-twelve-month earnings of $991M.
Does DexCom pay a dividend?: No regular cash dividend has been paid in the last year.
How much of DXCM is sold short?: 15.7M shares, 4.2% of float, as of Oct 15, 2026.
What sector is DXCM in?: Healthcare, in the Surgical Instruments industry.

About DexCom

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

HQ: San Diego, CA11,100 employeesListed Apr 14, 2005dexcom.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology